GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001
(0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear
Palsy, (PSP). In 75 patients diagnosed with PSPR Richardson(PSP-RS) or PSP-Parkinsonism
(PSP-P) at five hospitals in Korea, subcutaneous administration of GV1001 0.56 or 1.12 mg/day
will be conducted with multicenter, randomized, double-blind, placebo-controlled, parallel
design, prospective phase 2a.